Alto Neuroscience, Inc. announced the appointment of Maha Radhakrishnan, M.D. to the company?s board of directors. Dr. Radhakrishnan is an accomplished industry executive with decades of experience advancing large strategic portfolios across different therapeutic areas through product development and commercialization and overseeing the global medical strategy and operations within major biotechnology and pharmaceutical companies. Maha Radhakrishnan, M.D., recently served as group senior vice president and chief medical officer of Biogen, responsible for the worldwide medical function, until March 2024.

Previously, Dr. Radhakrishnan was senior vice president and global head of medical, primary care business unit at Sanofi, a global biopharmaceutical company focused on human health. At Sanofi, she led the function providing the medical strategy for the diabetes and cardiovascular products and programs in development. Prior, she held several leadership roles at Bioverativ Inc., Bristol Myers Squibb, United Health Group, and Cephalon.

Dr. Radhakrishnan received her M.D. in internal medicine with honors from the People?s Friendship University in Moscow, Russia in 1995, as well as a master's degree in Russian language.